Plasmatic and Platelet Anti-Plasmins and Anti-Activators

Summary

Direct antiplasmin and anti-urokinase can be measured with artificial clots to which plasma, serum or platelet suspension is added incubated in plasmin or urokinase respectively. Whilst only 3% of the total antiplasmin in the blood is present in the platelets, there is 40% of the total antiurokinase present in the platelets. The properties of this thrombocytic anti-urokinase are discussed. Only 60% is soluble in water. By heating this solution the inhibiting effect increases. Platelet anti-activator is also active against other activators but has not the same properties as anti-urokinase. Implications of these findings are discussed.

• References

• 1 Astrup T, Albrechtsen O. K. Estimation of the plasminogen activator and the trypsin inhibitor in animal and human tissue. Scand. J. clin. Lab. Invest 09: 233 1957;
• 2 Bennett N. B, Ogsten G. M, McAndrew G. M, Ogsten D. Studies in the fibrinolytic enzyme system in obesity. J. clin. Path 19: 241 1966;
• 3 Blix S. The effectiveness of activators in clot lysis with special reference to fibrinolytic therapy. Acta med. scand. suppl 386 1962;
• 4 Blix S. The quantitative determination of fibrinolytic inhibitors in plasma or serum by means of the fibrin plate. Scand. J. clin. Lab. Invest 16: 403 1964;
• 5 de Wit Dudok G. Fibrinolyse. Thesis; Amsterdam: 1962
• 6 Hawkey G. M, Stafford J. L. A standard clot method for the assay of plasminogen activators, antiactivators andplasmin. J. clin. Path 17: 175 1964;
• 7 Holemans R, Gross R. Influence of blood platelets in fibrinolysis. Thrombos. Diathes. haemorrh. (Stuttg) 06: 196 1961;
• 8 Jacobsen G. D. The antiplasmin activity of human plasma and serum and its dependence on ions. Scand. J. clin. Lab. Invest 16: 383 1964;
• 9 Johnson S. A, Schneider G. L. The existence of antifibrinolysin activity in platelets. Science 117: 229 1953;
• 10 Moers A. M. J. De meting van fibrinolyse. Thesis; Amsterdam: 1962
• 11 Moriau M, de Vries S. I, Dik H. J. Les inhibiteurs de la fibrinolyse et le dosage de l’activité antiplasminique, physiologique et pathologique. Thrombos. Diathes. haemorrh. (Stuttg) 10: 355 1963;
• 12 Naeye R. L. Thrombotic disorders with increased levels of antiplasmin and antiplasminogen. New Engl. J. Med 265: 867 1961;
• 13 Nilsson I. M, Björkman S. E, Studintz W. v, Hellem A. Antifibrinolytic activity of certain pectins. Thrombos. Diathes. haemorrh. (Stuttg) 06: 177 1961;
• 14 Nilsson I. M, Krook H, Sternberg N. H, Söderberg E, Söderström N. Severe thrombotic disease in a young man with bone marrow and skeletal changes and with a high content of an inhibitor in the fibrinolytic system. Acta med. scand 169: 323 1961;
• 15 Norman P. S, Hill B. M. Studies of the plasmin system III, physical properties of the two plasmin inhibitors in plasma. J. exp. Med 108: 639 1958;
• 16 Paraskevas M, Nilsson I. M, Martinsson G. A method for determining serum inhibitors of plasminogen activation. Scand. J. clin. Lab. Invest 14: 138 1962;
• 17 Phillips L. L, Skrodelis V. The fibrinolytic enzyme system in normal hemorrhagic and disease status. J. clin. Invest 37: 965 1958;
• 18 Tsitouris G, Bellet S, Eilberg R, Feinberg L. Effects of major surgery on plasmin — plasminogen inhibitors. Arch. int. Med 108: 208 1961;
• 19 de Vries S. I, Braat-van Straaten M. A. J, Müller E, Weitermark M. Antiplasmin deficiency in polycythemia; a form of thrombopathy. Thrombos. Diathes. haemorrh. (Stuttg) 06: 445 1961;
• 20 de Vries S. I, Braat-van Straaten M. A. J, Müller E, Weitermark M. Fibrinolyse door ontbreken van antifibrinolysine : een vorm van thrombopathie. Ned. Tdsch. Geneesk 105: 1623 1961;
• 21 de Vries S. I, Braat-van Straaten M. A. J, Müller E. Haemorrhagische diathese door het ontbreken van antiplasmine, behandeld met pinda’s. Ned. Tdsch. Geneesk 106: 1384 1962;
• 22 de Vries S. I. M, Braat-van Straaten A. J, Oey-Müller E. M. De invloed van enkele plantaardige Produkten op het fibrinolytische procès. Ned. Tdsch. Geneesk 106: 1840 1962;